| Literature DB >> 26232247 |
Karsten Schmidt1, Jochen Frederick Hernekamp2, Miriam Doerr3, Aleksandar R Zivkovic4, Thorsten Brenner5, Andreas Walther6, Markus A Weigand7, Stefan Hofer8.
Abstract
BACKGROUND: Microvascular permeability and leukocyte adhesion are pivotal mechanisms in sepsis pathophysiology contributing to the development of shock and mortality. No effective pharmacological therapy is currently available to restore microvascular barrier function in sepsis. Cholinergic mediators have been demonstrated to exert anti-inflammatory effects during inflammation. Cytidine-5-diphosphocholine (CDP-choline) is an extensively studied cholinergic drug due to its brain protective characteristics in cerebrovascular diseases. This study evaluated the effect of CDP-choline on microvascular permeability and leukocyte adhesion during endotoxemia.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26232247 PMCID: PMC4522138 DOI: 10.1186/s12871-015-0086-9
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Fig. 1Experimental protocol. Intravital microscopic measurements (IVM) were performed at 0-, 60-, and 120- min in endotoxemic and nonendotoxemic animals following a stabilization period after surgical preparation. LPS (4 mg/kg/h) or an equivalent volume of saline was continuously infused starting directly after baseline IVM at 0 min. CDP-choline (100 mg/kg) was applied as an i.v. bolus in treatment groups. All administered fluids were calculated to guarantee that all animals received equal amounts of intravenous fluids. The color and number code of the experimental groups introduced in this figure is used in all other figures
Fig. 2Effect of CDP-choline administration on macromolecular leakage during endotoxemia. Macromolecular leakage is expressed as ratio of perivenular to venular fluorescence intensity in arbitrary units. CDP-choline reduced microvascular permeability in postcapillary venules during endotoxemia. These results indicate that CDP-choline has a protective effect on microvascular permeability. Scatterplots with medians are displayed. *Significant difference vs. LPS (v). Medians with interquartile range (Q1–Q3) and p values are presented in Table 1
Fig. 4Effect of CDP-choline administration on leukocyte adherence during endotoxemia. CDP-choline had no effect on the number of adhering leukocytes during endotoxemia. Scatterplots with medians are displayed. * Significant difference vs. LPS (v). Medians with interquartile range (Q1–Q3) and p values are presented in Table 2
Summarized results of macromolecular leakage
| Time after induction of endotoxemia | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 min | 60 min | 120 min | ||||||||||
| Macromolecular leakage [arbitrary units] | Median | IQR (Q1-Q3) | * | Median | IQR (Q1-Q3) | *1 | #2 | Median | IQR (Q1-Q3) | * | # | |
| NaCI | (i) | 0.075 | 0.05-0.09 | ns3 | 0.15 | 0.11-0.2 | <0.0001 | 0.0002 | 0.22 | 0.14-0.29 | <0.0001 | <0.0001 |
| CDP-choline prior to NaCI | (ii) | 0.067 | 0.05-0.09 | ns | 0.11 | 0.07-0.21 | <0.0001 | 0.0054 | 0.21 | 0.08-0.36 | <0.0001 | 0.0008 |
| CDP-choline prior to LPS | (iii) | 0.095 | 0.07-0.12 | ns | 0.24 | 0.12-0.42 | 0.0141 | <0.0001 | 0.35 | 0.15-0.51 | 0.0019 | <0.0001 |
| CDP-choline after LPS | (iv) | 0.095 | 0.06-0.12 | ns | 0.27 | 0.18-0.47 | ns | <0.0001 | 0.34 | 0.25-0.49 | 0.0022 | <0.0001 |
| LPS | (v) | 0.099 | 0.07-0.11 | 0.48 | 0.34-0.63 | <0.0001 | 0.6 | 0.51-0.71 | <0.0001 | |||
1 * significant adjusted p value vs. LPS (v)
2 # significant p value vs. 0 min
3 ns: not significant
Summarized numbers of adherent leukocytes
| Time after induction of endotoxemia | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 min | 60 min | 120 min | ||||||||||
| Adherent leukocytes [cells/ mm2] | Median | IQR (Q1-Q3) | * | Median | IQR (Q1-Q3) | *1 | #2 | Median | IQR (Q1-Q3) | * | # | |
| NaCI | (i) | 140 | 59-218 | ns3 | 172 | 85-201 | 0.0139 | ns | 136 | 74-216 | <0.0001 | ns |
| CDP-choline prior to NaCI | (ii) | 206 | 75-268 | ns | 204 | 108-251 | ns | ns | 220 | 147-337 | 0.015 | ns |
| CDP-choline prior to LPS | (iii) | 204 | 165-250 | ns | 243 | 169-375 | ns | 0.0175 | 322 | 234-423 | ns | <0.0001 |
| CDP-choline after LPS | (iv) | 239 | 128-271 | ns | 305 | 232-351 | ns | <0.0001 | 342 | 226-418 | ns | 0.0003 |
| LPS | (v) | 193 | 118-280 | 267 | 193-358 | 0.0038 | 403 | 224-562 | <0.0001 | |||
1 * significant adjusted p value vs. LPS (v)
2 # significant p value vs. 0 min
3 ns: not significant
Summarized macro- and microhemodynamic parameters
| Time after induction of endotoxemia | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 min | 60 min | 120 min | ||||||||||
| Mean arterial pressure [mmHg] | Median | IQR (Q1-Q3) | * | Median | IQR (Q1-Q3) | *1 | #2 | Median | IQR (Q1-Q3) | * | # | |
| NaCI | (i) | 117 | 100-126 | ns3 | 131 | 125-137 | 0.0037 | ns | 133 | 118-145 | 0.0386 | ns |
| CDP-choline prior to NaCI | (ii) | 108 | 101-118 | ns | 117 | 93-132 | ns | ns | 133 | 104-139 | ns | ns |
| CDP-choline prior to LPS | (iii) | 105 | 97-123 | ns | 105 | 101-114 | ns | ns | 113 | 60-117 | ns | ns |
| CDP-choline after LPS | (iv) | 106 | 94-120 | ns | 105 | 89-120 | ns | ns | 114 | 100-122 | ns | ns |
| LPS | (v) | 103 | 89-109 | 99 | 89-104 | ns | 106 | 97-112 | ns | |||
| Heart rate [min−1] | Median | IQR (Q1-Q3) |
| Median | IQR (Q1-Q3) |
| # | Median | IQR (Q1-Q3) | * | # | |
| NaCI | (i) | 322 | 317-344 | ns | 371 | 332-403 | 0.0037 | 0.0002 | 395 | 326-441 | 0.0327 | <0.0001 |
| CDP-choline prior to NaCI | (ii) | 358 | 338-411 | ns | 408 | 400-473 | ns | 0.0313 | 433 | 428-470 | ns | 0.0313 |
| CDP-choline prior to LPS | (iii) | 375 | 351-456 | ns | 475 | 447-566 | ns | 0.0156 | 449 | 441-493 | ns | 0.0313 |
| CDP-choline after LPS | (iv) | 353 | 287-380 | ns | 381 | 326-432 | ns | 0.0117 | 445 | 358-476 | ns | 0.0039 |
| LPS | (v) | 340 | 320-353 | 410 | 391-436 | 0.0078 | 491 | 435-516 | 0.0078 | |||
| Venular wall shear rate [s−1] | Median | IQR (Q1-Q3) | * | Median | IQR (Q1-Q3) | * | # | Median | IQR (Q1-Q3) | * | # | |
| NaCI | (i) | 400 | 352-575 | ns | 505 | 413-642 | ns | 0.0006 | 444 | 368-573 | ns | ns |
| CDP-choline prior to NaCI | (ii) | 550 | 427-653 | ns | 420 | 356-614 | ns | ns | 302 | 230-631 | ns | 0.0395 |
| CDP-choline prior to LPS | (iii) | 436 | 367-567 | ns | 362 | 274-553 | ns | 0.0229 | 311 | 120-497 | ns | 0.0009 |
| CDP-choline after LPS | (iv) | 503 | 407-582 | ns | 397 | 321-505 | ns | 0.0301 | 443 | 281-590 | ns | 0.0254 |
| LPS | (v) | 499 | 405-622 | 378 | 251-523 | ns | 348 | 285-493 | 0.0026 | |||
1 * significant adjusted p value vs. LPS (v)
2 # significant p value vs. 0 min
3 ns: not significant
Fig. 3IVM images demonstrating the CDP-choline effect on microvascular permeability during endotoxemia. Fluorescent IVM images show postcapillary venules recorded at 0 min (upper panels) and 120 min after the treatment (lower panels). LPS administration alone (v) induces distinctive macromolecular leakage compared to the baseline measurement at 0 min and to the NaCl group (i). Note the effect of CDP-choline on reducing macromolecular leakage in endotoxemic animals (iii, iv) compared to the LPS group (v)